We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety of pitolisant: a study in the WHO international pharmacovigilance database.
- Authors
Montastruc, Jean-Louis
- Abstract
The article focuses on Pitolisant which is new drug with a new mechanism of action, inverse agonist at the H3 histamine receptor, marketed in narcolepsy and excessive daytime sleepiness in obstructive sleep apnea syndrome. Topics include examines the clinical trials found that its main adverse events are neuropsychiatric, including headache, insomnia, anxiety, and depression, but also vomiting and weight gain.
- Subjects
INSOMNIA risk factors; MIGRAINE risk factors; HEADACHE risk factors; RISK factors of aggression; MENTAL depression risk factors; NAUSEA -- Risk factors; WORLD Health Organization; PHARMACOLOGY; DIZZINESS; ANTIHISTAMINES; CELL receptors; PIPERIDINE; SLEEP disorders; NARCOLEPSY; ITCHING; ANXIETY; PATIENT safety; DISEASE risk factors
- Publication
European Journal of Clinical Pharmacology, 2023, Vol 79, Issue 4, p569
- ISSN
0031-6970
- Publication type
Article
- DOI
10.1007/s00228-023-03460-0